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ABSTRACT
Objective: The objective of the study was to establish the anti-inflammatory and anti-arthritic potential of various fractions of Eclipta prostrata Linn.
Methods: The four fractions, i.e., n-butanol, ethyl acetate, chloroform, and n-hexane from hydro-alcoholic extract were obtained. First, the fractions 
were evaluated through in vitro models, and then they were evaluated by in vivo anti-inflammatory model, i.e., carrageenan-induced paw edema 
model. Further, two active fractions were evaluated for the anti-arthritic activity using formaldehyde induced arthritis model.
Results: The fractions at a dose of 100 and 200 mg/kg showed an anti-inflammatory activity, but the ethyl acetate and chloroform fraction will show 
maximum anti-inflammatory potential. Hence, they are further evaluated for anti-arthritic potential where they show significant activity.
Conclusion: From the results, it is concluded that the ethyl acetate and chloroform fraction show significant anti-arthritic activity.
Keywords: Inflammation, Arthritis, Eclipta prostrata, Wedelolactone.
INTRODUCTION
Arthritis and diseases of joints have been plaguing humankind since 
times. There is an indication of rheumatoid arthritis (RA) in the 
Egyptian mummies, as found in several studies. G. Elliot, in his studies, 
found that RA was a prevalent disease among Egyptians [1]. In Indian 
literature, Charak Samhita (300–200 B.C.) also described a clause that 
describes pain, joint swelling, and loss of joint morbidity, and functions. 
RA is a continual autoimmune disease characterized by joint swelling, 
synovial inflammation, and cartilage destruction and commonly leads 
to significant disability [2]. It affects about 1% of the population of the 
world.
The pathophysiological changes in RA include hyperplasia of the synovial 
membrane, permeation of inflammatory cells, and neovascularization, 
which eventually lead to cartilage erosion and articular destruction. 
Moreover, the etiology is disappointingly understood now, but 
inflammatory cytokines are considered to play a key role. One of the 
critical pathogenesis of RA is the over-look of inflammatory cytokines, 
including tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, 
interleukin-33, and rheumatoid factor in synovial membrane and 
serum [3]. Various mediators which are secreted by macrophages and 
other immune cells will be regulated, and modulation of arachidonic 
acid metabolism by inhibiting enzymes such as cyclooxygenase and 
lipoxygenase are main targets for chronic inflammatory conditions. 
However, various categories such as immunosuppressants, 
nonsteroidal anti-inflammatory drugs, and steroidal anti-inflammatory 
drugs are currently being used, but their side effects limit their use. Due 
to these reasons, growing concern exists for the development of a new 
safe, potent, and less toxic anti-arthritic drug. Hence, there is a must 
to discover for more naturally available drugs so that their therapeutic 
values can be assessed and expanded [4].
The genus Eclipta was described by Linnaeus, with three species, 
i.e., Eclipta erecta L., E. prostrata L., and Eclipta punctuate L. Eclipta 
species are characterized by being usually perennial herbs, found 
in damp or boggy situations, often on stream and lakesides and then 
facultative semi-aquatic, with vertical emergent flowering branches. 
The plants of this genus composed of numerous phytoconstituents 
and are utilized comprehensively in folk medicine and pharmaceutical 
industries [5].
E. prostrata is commonly known as bhringaraj and belongs to 
family Asteraceae. The word prostrata was derived from Latin word 
Prostratus, which refers to annual, weak, sprawling stems arising 
from a perennial, and woody rootstock. It is an erect or decumbent 
perennial herb, 30–60 cm tall having weak and scabrous stems. The 
plant is widely distributed in pantropical and warm temperate areas of 
South America. In Australia it is widespread in Queensland, Northern 
Territory, and north-east New South Wales; in Western Australia rare 
in the Kimberley and near Perth. It is commonly found in India, China, 
Taiwan, Philippines, Japan, and Indonesia. E. prostrata (L.) consists of 
nicotinamide about 0.08%, tannins, Vitamin A, ecliptine, and thiophene 
such as compounds such as triphenylmethanol and its acetate such 
as (2-[Buta-1, 3-diynyl]-5-[but-3-en-1-ynyl] thiophene) and (2-
[Buta-1, 3-diynyl]-5-[4-chloro-3-hydroxy but-1-ynyl] thiophene). 
Leaf extract mainly contains wedelolactone, demethylwedelolactone, 
demethylwedelolactone-7-glycosides, α-terthienylmethanol, and 
α-formyl-alpha-terthienyl, etc. The different parts of the plant such as 
leaves, roots, stems, and barks are used as antibacterial, antivenom, 
hepatoprotective, antihemorrhagic, anti-inflammatory, bronchodilator, 
anticancer, antiviral, analgesic, and antioxidant. According to Ayurvedic 
philosophy, E. prostrata is useful in inflammation, hernia, eye diseases, 
bronchitis, asthma, leukoderma, anemia, heart and skin diseases, 
blindness, and syphilis. The plant possesses various pharmacological 
activities, which include analgesic, hepatoprotective, hypoglycemic, 




Leaves of E. prostrata L. were collected in the month of November 2013 
from the campus of Kurukshetra University, Kurukshetra, Haryana, 
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India. Sample of leaves was authenticated by Dr. B. D. Vashistha, 
Chairman Department of Botany, Kurukshetra University, Kurukshetra, 
Haryana, India. For the purpose of any future reference, plant sample has 
been kept in the herbarium of the Department of Botany, Kurukshetra 
University under voucher specimen number KUK/BOT/IPS/17.
Preparation of hydro-alcoholic extract and fractions
Leaves of E. prostrata were washed under running tap water and dried 
under shade at room temperature for around 2 weeks. The dried leaves 
were ground into a coarse powder using pestle and mortar and stored 
in an airtight container. The powder was extracted with the opposite 
quantity of hydro-alcohol in a ratio of 30:70 by Soxhlet extraction at 
a temperature of 65°C–75°C. The extract obtained was solidified and 
further subject to fractionation using the method as described by 
Suffness and Douros (1979). The fractionation was done using four 
solvents using n-hexane, chloroform, ethyl acetate, and n-butanol. The 
extract was initially dissolved in 1:1 mixture of n-hexane and distilled 
water and the two phases were separated in separating funnel. After 
24 h, the two layers were separated and the solvent was removed 
from the n-hexane layer to obtain the n-hexane fraction (EPHF). To 
the water fraction equal quantity of chloroform was added and allows 
separation of two layers in separating funnel. After 24 h again, two 
layers were separated and similarly Chloroform fraction (EPCF) was 
obtained. Further, the water fraction was mixed with an equivalent 
volume of ethyl acetate in a separating funnel to obtain the Ethyl 
acetate fraction (EPEAF). Finally, the water fraction n-butanol was 
added in the same volume and allows separation in a separating funnel 
for 24 h. Thus, we obtained the n-butanol fraction (EPBF).
Preliminary phytochemical screening
The fractions obtained from the hydroalcoholic extract were subjected 
to preliminary phytochemical screening. About 5% solution of all the 
samples was prepared and filtered [7].
Animals
Wistar strain of albino rats (180–20 0g) was obtained from National 
Institute of Pharmaceutical Education and Research, Mohali. The 
animals were housed in the animal house of Institute of Pharmaceutical 
Sciences, Kurukshetra University, Kurukshetra. The animals were 
maintained under standard environmental conditions and were fed 
with standard pellet diet and water ad libitum. The study was approved 
by the Institutional Animal Ethics Committee (Reg. No. 263).
Dose preparation
The dose was selected on the basis of acute toxicity studies conducted 
on Wistar rats. The dose that should be administered to animals for 
the experiment would be 100 and 200 mg/kg. The dose of different 
fractions was prepared by reconstituting the required quantity of the 
fraction in Tween 80 (5% v/v in saline). The freshly prepared drug was 
administered to Wistar rats through the oral route (p.o.).
In vitro anti-inflammatory study
Preparation of red blood cells (RBCs) suspension
Sufficient amount of blood was withdrawn through cardiac puncture 
under light ether anesthesia, which was then transferred into a glass 
tube containing 1.8 mg/ml 5% ethylenediaminetetraacetic acid solution 
and mixed tenderly. The collected sample was centrifuged at 3000 rpm 
for 15 min and washed 3 times with an equal volume of normal saline. 
The blood suspension so obtained was measured and suspended in 
normal saline to obtain 10% v/v suspension. The prepared suspension 
was stored at 4°C and used within 6 h [8].
Heat-induced hemolysis
For the estimation, the reaction mixture was prepared in a test tube by 
placing 1 ml of 10% RBC suspension and different concentrations of 
test compound and standard drug. Moreover, for the purpose of control, 
an equal volume of normal saline was used. All the samples were 
incubated at 57°C for 30 min over a water bath followed by cooling 
under running tap water. Afterward, each sample was then centrifuged 
at 2500 rpm for about 5 min. The supernatant was removed carefully 
and examine spectrophotometrically at a wavelength of 560 nm.
In vitro anti-arthritic activity
Inhibition of protein denaturation
For determining the anti-arthritic activity, test solution was prepared 
by taking 1 ml of bovine serum albumin and 1 ml of test solution while 
standard solution consists of 1 ml of bovine serum albumin and 1 ml of 
diclofenac sodium.
The test solution includes fractions of n-hexane, chloroform, ethyl acetate, 
and n-butanol of leaves of E. prostrata. All the above solutions were then 
adjusted to pH 6.3 using 1N HCl. The samples were incubated at 37°C for 
30 min, and the temperature was increased to keep the samples at 57°C for 
5 min. The absorbance was measured using UV-Visible spectrophotometer 
at 660 nm. The control represents 100% protein denaturation [8].
Proteinase inhibitory activity
Proteinase inhibitory potential was studied according to the method 
of Oyedepo et al., 1995, with slight modifications. For the estimation 
different concentration of test, samples were prepared, which consists 
of 0.06 mg trypsin, 1 ml 20 mM Tris HCl, and 1 ml of test solution/
standard solution. All the samples were then incubated at 37°C for 
5 min, and 1 ml of 0.8% w/v casein was added to the reaction mixture 
followed by incubation at 37°C for 20 min. 2 ml of perchloric acid (70%) 
was added to each tube for termination of the reaction. All the samples 
were centrifuged at 3000 rpm for 20 min and were subjected to UV 
spectrophotometric analysis at 210 nm [8].
Membrane stabilization test/inhibition of membrane lysis
The principle involved here is stabilization of human RBC (HRBC) 
membrane by hypotonicity induced membrane lysis. The assay 
mixture contains 1 ml phosphate buffer (pH 7.4, 0.15 M), 2 ml hypo 
saline (0.36%), and 0.5 ml HRBC suspension (10 % v/v) with 0.5 ml 
of plant fractions and standard drug diclofenac sodium of various 
concentrations (50, 100, 250, 500, 1000, and 2000 μg/ml) and control 
(distilled water instead of hypo saline to produce 100% hemolysis) 
which were incubated at 37°C for 30 min and centrifuged, respectively. 
The hemoglobin content in the suspension was estimated using 
spectrophotometer at 560 nm, and percentage inhibition of membrane 
stabilization can be calculated [8].
In vivo anti-inflammatory study
Carrageenan-induced paw edema
Wistar albino rats were starved overnight and were divided into 11 
different groups, consisting of five animals in each group, according to 
the treatment given to them. Group I animals are considered as control 
receiving neither fraction nor carrageenan while Group II (negative 
control) animals receive the only carrageenan. Groups III and IV 
received EPHF at the dose of 100 and 200 mg/kg. Similarly, in Groups V 
and VI, EPCF was administered at the same doses. EPEAF at a dose of 
100 and 200 mg/kg was administered to Groups VII and VIII and EPBF 
were given to Groups IX and X. Finally, standard drug diclofenac sodium 
at a dose of 5mg/kg was administered to Group XI. To ensure uniform 
hydration, the rats receive 5 ml of water by stomach tube (controls) or 
the test drug dissolved/suspended in 5% v/v Tween 80. Thirty minutes 
later, the rats were challenged by subcutaneous injection of 0.1 ml of 
1% solution of carrageenan into the plantar side of the left hind paw. 
The paw is marked with ink at the level of the lateral malleolus and 
immersed in mercury up to this mark. The paw volume was measured 
plethysmographically immediately after injection and then after 1 h, 2 h, 
3 h, and 6 h and eventually 24 h after challenge. Results thus obtained 
for various dosage groups would be further subjected to statistical 
analysis and were compared with standard and control group [9].
Formaldehyde-induced arthritis
Wistar rats were starved overnight and divided into seven groups 
depending on the results obtained in the above model. Each group 
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includes five animals. On day 1, 30 min after the vehicle/standard/test 
drug administration chronic non-immunological arthritis was induced 
by subplantar injection of 0.1 ml of 2% formaldehyde solution and 
similar treatment was given on day 3.
Group I animals will be acts as a control group which neither receives 
any noxious stimulus nor any treatment while in Group II 0.1 ml of 
2% formaldehyde solution is injected in the left paw. Groups III and 
IV would receive a dose of 100 mg/kg and 200 mg/kg of EPA fraction. 
On the other hand, Groups V and VI received EPCF at similar doses. 
Finally, Group VII was considered as a standard group which received 
diclofenac sodium at a dose of 5 mg/kg [9].
Statistical analysis
All experiments were conducted in triplicate and values expressed as 
the mean ± standard deviation. Variations in mean were calculated 




Pharmacologically active EPHF, EPCF, EPBF, and EPAF fractions were 
screened for the phytochemical study. The results are shown in Table 1.
Heat-induced hemolysis
It is of particular concern to investigate the in vitro anti-inflammatory 
properties of medicinal plants, especially those traditionally used in 
folk medicine. In the present study, the stabilization of erythrocyte 
membranes exposed to heat-induced lyses was employed. The 
fractions of a hydroalcoholic extract of E. prostrata have shown 
significant activity at various concentrations, and its effect 
was compared with the standard drug diclofenac sodium. The 
chloroform fraction shows an excellent percentage of protection of 
64.56% when compared with the standard. Moreover, EPEAF also 
shows a good percentage of protection of 62.33%. The maximum 
percentage membrane stabilization of fractions of E. prostrata was 
observed at 1000 μg/ml, respectively, as shown in Fig. 1, whereas 
diclofenac sodium shows comparative protection at a concentration 
of 750 µg/ml.
Inhibition of protein denaturation
Production of autoantigen in certain arthritic disease is due to 
denaturation of proteins. The mechanism of denaturation involves 
alteration in electrostatic hydrogen, hydrophobic, and disulfide 
bonding. From the results of the present study, it can be stated that the 
fractions of E. prostrata leaves are capable of controlling the production 
of autoantigen and thereby it inhibits the denaturation of proteins 
and its effect was compared with the standard drug diclofenac. The 
maximum percentage of protection was shown by chloroform fraction 
(82.16%) than by the ethyl acetate fraction (81.24%). From Fig. 2, it can 
be clearly observed that chloroform and ethyl acetate fraction exhibits 
the comparative percentage protection. However, EPBF also showed 
good inhibition in protein denaturation with percentage activity of 
78.38%. Obtained data showed that EPCF and EPEAF could be used as 
a potent anti-arthritic agent.
Proteinase inhibitory activity
Proteinase inhibitory action was studied to establish the mechanism 
of the anti-arthritic effect of various fractions of E. prostrata. The 
production of auto-antigens in certain arthritic diseases may be due 
to proteinase action. From the results depicted in Fig. 3, it reveals that 
EPCF and EPEAF fractions are capable of inhibiting proteinase action 
Table 1: Preliminary phytochemical screening of plant fractions
S.No. Tested for Chemical test Inference
EPHF EPCF EPEAF EPBF
1 Acidic compounds Sodium-bicarbonate test + + - -
Litmus test + + - -
2 Alkaloids Dragons off test - - + +
Meyer’s test - + + +
Wagner’s test - + + +
Hager’s test - - + +
3 Amino acids Millon’s test - - - +
Ninhydrin test - - + +
4 Carbohydrates Molisch’s test + + + +
Fehling’s test - + + +
Benedict’s test + + + +
5 Lignin Phloroglucinol test - - - -
6 Volatile oil Sudan III test - - + +
7 Fats and fixed oil Sodium hydrogen sulfate - + + +
CuSO4/NaOH - + + +
8 Flavonoids Shinoda test - + + +
Lead acetate test - + + +
Alkaline reagent test - - + +
9 Glycosides Borntrager’s test - - + +
Modified Borntrager’s test - + + +
Hydroxy anthraquinone - - - -
Keller–killini test - - + +
Raymond’s test - - - -
Legal’s test - - + +
Baljet’s test - - - +
Froth formation test - - + +
10 Tannins Ferric chloride test + + + +
Gelatin test + + + +
Test for catechin + + + +
Test for chlorogenic acid + + + +
11 Protein Biuret test - + + +
Hydrolysis test - + + +
12 Steroids Liebermann–Burchard test + ++ ++ +
Salkowski test + ++ ++ +
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Fig. 1: Comparison of the anti-arthritic activity of fractions of E. prostrata and diclofenac sodium on hemolysis
Fig. 2: Comparison of the activity of fractions of E. prostrata and diclofenac sodium on protein denaturation
Fig. 3: Comparison of the anti-arthritic activity of fractions of E. prostrata and diclofenac sodium on proteinase inhibitory activity
in rheumatic diseases. Moreover, results obtained for the chloroform 
fraction showed 77.31% proteinase inhibition when compared with 
standard diclofenac at a concentration of 1 mg/ml. The percentage 
inhibition in proteinase inhibitory activity for EPEAF was 74.68%.
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Fig. 6: Anti-inflammatory activity of chloroform fraction of E. prostrata
Fig. 4: Comparison of the anti-arthritic activity of fractions of E. prostrata and diclofenac sodium on membrane stabilization
Fig. 5: Anti-inflammatory activity of n-butanol fraction of E. prostrata
Membrane stabilization test/Inhibition of membranolysis
In the present study, the stabilization of erythrocyte membranes exposed 
to hypotonic induced lysis was employed. The erythrocyte membrane is 
analogous to the lysosomal membrane and its stabilization implies that 
the extract may as well stabilize lysosomal membranes. The fractions 
exhibited membrane stabilization effect by inhibiting hypotonicity 
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Fig. 8: Anti-inflammatory activity of ethyl acetate fraction of E. prostrata
Fig. 9: Anti-arthritic effect of chloroform fraction of E. prostrata leaf in formaldehyde induced arthritis model in rats
Fig. 7: Anti-inflammatory activity of n-hexane fraction of E. prostrata in carrageenan-induced paw edema
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induced lysis of the erythrocyte membrane. The chloroform and 
ethyl acetate fractions of E. prostrata had shown significant activity 
at various concentrations, and its effect was compared with the 
standard drug diclofenac. In the case of ethyl acetate fraction, the 
percentage scavenging activity at a concentration of 750 µg/ml does 
not show a dose-dependent increase in the activity, while chloroform, 
n-butanol, and n-hexane fraction show a dose-dependent activity. At 
certain concentration, the EPEAF and EPBF exhibit similar percentage 
scavenging activity. The maximum percentage membrane stabilization 
of EPCF and EPEAF was observed as 74.07 and 70.24, respectively, at a 
concentration of 1000 µg/ml. The results are depicted in Fig. 4.
Carrageenan-induced paw edema
The anti-inflammatory potential of n-hexane, chloroform, ethyl acetate, 
and n-butanol fraction of hydroalcoholic extract of leaves of E. prostrata 
was investigated using the carrageenan-induced paw edema method. 
As shown in Table 2, the fractions obtained from hydroalcoholic extract 
at doses of 100 and 200 mg/kg body weight showed significant and 
dose-dependent inhibition in inflammation induced by carrageenan. 
The maximum inflammation was seen after 3 h of injecting carrageenan 
in paw in each group.
As depicted in Fig. 5 the EPBF does not reduce paw inflammation 
significantly with standard while EPCF shows a more significant 
reduction in paw volume with respect to diclofenac as mentioned in 
Fig. 6. Whereas EPHF and EPEAF has show somewhat reduction in paw 
volume as depicted in Figs 7 and 8.
The results revealed that chloroform and ethyl acetate fraction at a dose 
of 200mg/kg show maximum inhibition of inflammation of 26.92% and 
23.86%, respectively. In addition, n-hexane (22.76%) and n-butanol 
(17.07%) fractions also show significant inhibition of inflammation in 
carrageenan-induced paw edema model when compared with standard. 
However, standard drug (diclofenac sodium, 5 mg/kg) showed highly 
significant inhibition at the same time with the maximum percentage 
inhibition when compared to the control group, as shown in Table 3.
Formaldehyde-induced arthritis
The figures obtained from the carrageenan-induced paw edema model 
showed that chloroform and ethyl acetate fraction have maximum anti-
inflammatory activity. Thus in formaldehyde induced arthritis models, 
the anti-arthritic potential of EPCF and EPEAF would be evaluated. The 
formaldehyde test is a sensitive and valid model for various classes of 
anti-arthritic drugs. It produces a biphasic response and different drugs 
may act differently in the early and late phase of the test. The effects of 
EPCF and EPEAF at the dose of 100 and 200 mg/kg on formaldehyde 
induced arthritis are shown in Table 4. The data depicted in Tables 4 
and 5 showed that EPCF at both doses exhibits significant anti-arthritic 
activity, while EPEAF at a dose of 100 mg/kg had a lesser anti-arthritic 
activity than 200 mg/kg when compared to control.
In the negative control group, the foot volume reached its maximum 
value on the 7th day and thereafter decreased slightly by the 8th day. 
As depicted in Fig. 9 the animals treated with EPCF (100 and 200 mg/
kg) showed maximum swelling on the 5th day, and the foot volume was 
reduced on the 9th day. In EPEAF (200 mg/kg) treated animals maximum 
swelling was noticed on the 6th day and then decline in paw volume was 
observed till the end of the study which is clearly observed from Fig. 10.
DISCUSSION
Eclipta herbs have been commonly used to treat joint pain and arthritis 
worldwide. In this study, we investigated the anti-inflammatory and 
anti-arthritic effects of E. prostrata fraction. Plant-derived drug has been 
demonstrated to contain principles that possess the ability to facilitate 
the stability of biological membranes when exposed to induced lysis. 
EPCF and EPEAF were found to possess very good membrane stabilizing 
property, which is one of the preliminary steps involved in the screening 
of anti-inflammatory and anti-arthritic property. The mode of action of 
the extracts and standard anti-inflammatory drugs could be connected 
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with binding to the erythrocyte membranes with subsequent alteration 
of the surface charges of the cells. This might have prevented physical 
interaction with aggregating agents or promote dispersal by the mutual 
Fig. 10: Anti-arthritic effect of ethyl acetate fraction of E. prostrata leaf in formaldehyde induced arthritis model in rats
Table 3: Percentage Inhibitory effect of n-hexane, chloroform, ethyl acetate, and n-butanol fractions of Eclipta prostrata leaves against 
carrageenan-induced paw edema in rats
Drug Dose (mg/kg) Percentage inhibition in paw volume
0 h ½ h 1 h 1.5 h 2 h 3 h 6 h 24 h
Diclofenac sodium 5 6.94 15.05 21.69 23.57 25.38 36.73 27.2 19.58
EPHF 100 7.79 21.50 22.64 23.57 22.30 20.72 16.00 5.15
EPHF 200 8.86 18.25 20.75 22.76 21.95 19.40 19.26 9.27
EPCF 100 7.79 17.20 18.86 25.20 26.15 26.11 24.8 15.46
EPCF 200 10.38 15.05 21.69 26.01 26.92 23.13 22.4 19.58
EPEAF 100 5.94 13.97 16.03 20.32 21.53 19.40 18.04 8.20
EPEAF 200 5.19 10.75 14.15 19.51 20.76 23.86 19.20 10.30
EPBF 100 5.19 8.6 10.37 17.07 16.15 15.67 14.40 5.15
EPBF 200 1.29 3.61 16.03 17.07 15.38 14.17 14.10 8.2
Table 4: Anti-arthritic activity of chloroform and ethyl acetate fraction of E. prostrata in formaldehyde induced arthritis
Treatment Control Negative control Diclofenac sodium EPCF EPCF EPEAF EPEAF
Groups I II III IV V VI VII
Dose - 0.1 ml 5 mg/kg 100 mg/kg 200 mg/kg 100 mg/kg 200 mg/kg
Mean PAW 
volume (ml)
Day 1 0.84±0.03** 1.13±0.04 1.16±0.02 (NS) 1.14±0.03 (NS) 1.19±0.01** 1.17±0.02 (NS) 1.18±0.02*
Day 2 0.83±0.3** 2.81±0.03 2.43±0.03** 2.62±0.02 (NS) 2.51±0.03** 2.64±0.02 (NS) 2.54±0.03*
Day 3 0.78±0.03** 3.89±0.03 3.22±0.04** 3.52±0.02** 3.32±0.02** 3.58±0.06** 3.36±0.03**
Day 4 0.73±0.03** 4.37±0.04 3.58±0.05** 3.75±0.02** 3.64±0.04** 3.87±0.03** 3.72±0.03**
Day 5 0.87±0.03** 5.06±0.04 3.98±0.03** 4.24±0.03** 4.11±0.04** 4.360.04** 4.21±0.02**
Day 6 0.91±0.02** 5.91±0.03 4.32±0.03** 4.90±0.02** 4.67±0.02** 5.14±0.03** 4.79±0.07**
Day 7 0.81±0.02** 5.85±0.03 4.14±0.05** 4.92±0.04** 4.40±0.03** 5.10±0.02** 4.51±0.02**
Day 8 0.83±0.01** 4.88±0.06 3.89±0.03** 4.31±0.03** 4.04±0.03** 4.39±0.03** 4.15±0.04**
Day 9 0.88±0.02** 4.07±0.05 3.39±0.06** 3.66±0.03** 3.46±0.04** 3.71±0.02** 3.58±0.02**
Day 10 0.78±0.03** 2.83±0.05 2.46±0.02** 2.68±0.04** 2.49±0.01** 2.71±0.04** 2.54±0.02**
Values are expressed as (mean±SD), n=5, **p<0.01, *p<0.05 when compared with the control group (statistically analyzed by Dunnet’s t-test). NS: Not significant, 
SD: Standard deviation
Table 5: Inhibitory effect of chloroform and ethyl acetate fraction of Eclipta prostrata in formaldehyde induced arthritis in rats
Drug/extract Percentage inhibition in paw volume
Day 1 2 3 4 5 6 7 8 9 10
Diclofenac sodium 2.65 13.52 17.22 19.91 21.34 26.90 29.23 20.28 16.70 13.07
EPCF (100 mg/kg) 0.88 6.76 9.51 14.18 16.20 17.08 15.89 11.68 10.07 5.30
EPCF (200 mg/kg) 5.30 10.67 14.65 16.70 18.77 20.98 24.78 17.21 14.98 12.01
EPEAF (100 mg/kg) 3.53 6.04 8.65 11.44 16.05 13.02 12.82 10.04 8.84 4.24
EPEAF (200 mg/kg) 4.42 9.61 15.77 17.47 16.79 18.95 22.90 14.95 12.03 10.24
repulsion of like charges which are involved in the hemolysis of RBCs. It 
has been reported that certain saponins and flavonoids exerted a profound 
stabilizing effect on lysosomal membrane both in vivo and in vitro, 
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while tannins and saponins possess the ability to bind cations, thereby 
stabilizing erythrocyte membranes and other biological macromolecules.
Proteinases have been implicated in arthritic reactions. Neutrophils are 
known to be a rich source of proteinase which carries in their lysosomal 
granules many serine proteinases. It was previously reported that leukocytes 
proteinase play an important role in the development of tissue damage 
during inflammatory reactions and significant level of protection was 
provided by proteinase inhibitors. Inhibition of protein denaturation and 
proteinase inhibitory action was studied to establish the mechanism of the 
anti-arthritic effect of fractions of E. prostrata. Hence, the anti-arthritic effect 
of EPCF and EPEAF was studied significantly using in vitro models, and it can 
be concluded that both the fractions can serve as an anti-arthritic agent.
The anti-inflammatory effects of the herb were assessed by swelling 
in the left foot of the rat induced through carrageenan solution. 
First, substantial inflammation was induced in the lateral left foot, as 
demonstrated by increased paw volume. The study was conducted to 
evaluate the anti-inflammatory potential of E. prostrata in laboratory 
animals using carrageenan-induced paw edema, anti-inflammatory 
models. Carrageenan-induced rat paw edema model is a widely accepted 
model for the study of anti-inflammatory activity of compounds. Edema 
was induced in the left paw of rats following subplantar injection of 0.1 ml 
of 1% solution of carrageenan, which results in inflammation due to the 
release of serotonin, histamine, and prostaglandin-like substances. Oral 
administration of the four fractions of E. prostrata at a dose of 100 and 
200 mg/kg significantly suppressed inflammation, and the reductions 
were 26.92%, 23.86%, 22.76%, and 17.07% for chloroform, ethyl acetate, 
n-hexane, and butanol fractions, respectively, at the end of treatment.
Based on the results obtained for the fractions of E. prostrata in the 
above method, EPCF and EPEAF were examined for their anti-arthritic 
potential by formaldehyde-induced arthritis in rats. Estimation of the 
ability of fractions to inhibit formaldehyde-induced edema in rats is 
documented as the most suitable method for screening anti-arthritic 
compounds. In rat foot, when formaldehyde was injected, it produces 
localized inflammation and pain when injected into the paw of rat, 
which is biphasic comprising of early neurogenic component and a 
later tissue mediated response. The result of the formaldehyde-induced 
arthritis study showed both dose- and time-dependent reduction of the 
paw thickness by both the fractions as well as the reference drug and 
therefore suggests that chloroform fraction and ethyl acetate fractions 
of E. prostrata may be effective in the management of arthritis.
CONCLUSION
In the view of above discussion, it is conceivable that E. prostrata has 
been observed to exert significant anti-arthritic effect in experimental 
studies. Furthermore, ethyl acetate and chloroform fraction has been 
reported to be most potent. In summary, this contemporary research 
lends pharmacological support to reported folkloric usage of plant 
in the treatment and management of painful arthritic inflammatory 
conditions. Based on our results, further thorough studies are 
required for appraisal of exact mechanism of action, determination 
of pro-inflammatory cytokines level, isolation of active constituents 
and cellular characterization that could conclusively establish 
E. prostrata as a potentially safer disease modifying agent in the 
treatment of RA.
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